Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.
Investor's Business Daily on MSN36m
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1Novo Nordisk will pay Lexicon $1 billion up front to license its experimental obesity treatment. The news sent penny stock Lexicon flying.
The drug has been approved to help treat type-2 diabetes, but a new study shows an increase in use in people with type-1 diabetes, and it may not be safe.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback